Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

NCT05094336 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05094336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05094336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 1, 2022
Completion date
November 30, 2026
Enrollment
329 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

advanced mtap-null solid tumors